Table 2 Patient and transplant characteristics of the genotyped cohort (N = 48)
From: Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation
N (% or IQR) | ||
|---|---|---|
Median Age at HCT | 49 (20–73) | |
Disease | ||
AML | 35 (73%) | |
MDS | 13 (27%) | |
Disease status at transplant | ||
CR1 | 32 (67%) | |
CR2 | 16 (33%) | |
Donor type | ||
MRD | 20 (42%) | |
MUD | 20 (42%) | |
Haplo | 8 (16%) | |
Graft type | ||
BM | 26 (54%) | |
PBSC | 22 (46%) | |
Conditioning regimen | ||
RIC | 25 (52%) | |
MAC | 23 (48%) | |
Median FUP (months) | 12.33 (2.4–109.5) | |
Acute GvHD (II-IV) | 16 (33%) | |
Chronic GvHD (moderate-severe) | 10 (20%) | |
Median time of relapse after HCT (months) | 5.8 (1.67–56.3) | |
DLI recipients | 25 (52%) | |
Time to DLI (months) | 7.8 (2.9–61.08) | |
Extramedullary disease at relapse | 4 (8%) | |
